Schizophrenia and Related Disorders

Chapter
First Online:

Abstract

Optimizing the person-centred approach for the diagnosis and treatment of schizophrenia and related mental disorders poses several challenges. There is a need to redefine the role of the diagnostic process for the person with schizophrenia, in that it should include symptoms and a holistic assessment of the whole person and his/her reaction, social consequences and functional impairments. Such a person-centred reconceptualization may have consequences for studies addressing patient-centred outcomes and efficacy measures of therapeutic procedures. This will involve issues of shared decision making, empowering patients with schizophrenia, reducing symptoms, disabilities and the stigma of mental disorders as well as promoting wellbeing. Furthermore, future research into the etiopathogenesis of schizophrenia and related disorders will need to take into account the (neuro)biology, psychological and social aspects of the psychotic disorders, and not focus on one of these aspects solely. New research initiatives like the Research Domain Criteria initiative of the US National Institutes of Mental Health and new trends in the psychosocial care for people with schizophrenia are increasingly shaping the field in such a direction. Integrating the role of childhood trauma and other socioenvironmental aspects into the concept of schizophrenia and its context, and reconciling these domains with the (neuro)biological approach are promising to advance the person-centredness of mental health care for people with schizophrenia and related disorders.

Keywords

Schizophrenia and related disorders Personalized care Person-centred care Education and research 
This is a preview of subscription content, log in to check access.

References

  1. 1.
    Akdeniz C, Tost H, Meyer-Lindenberg A. The neurobiology of social environmental risk for schizophrenia: an evolving research field. Soc Psychiatry Psychiatr Epidemiol. 2014;49:507–17.CrossRefPubMedGoogle Scholar
  2. 2.
    Arnedo J, Svrakic DM, Del Val C, Romero-Zaliz R, Hernandez-Cuervo H, Molecular Genetics of Schizophrenia Consortium, Fanous AH, Pato ME, Pato CN, de Erausquin GA, Cloninger R, Zwir I. Uncovering the hidden risk architecture of the schizophrenias: confirmation in three independent genome-wide association studies. Am J Psychiatry. 2015;172:139–53.CrossRefGoogle Scholar
  3. 3.
    Bachmann S, Resch F, Mundt C. Psychological treatments for psychosis: history and overview. J Am Acad Psychoanal Dyn Psychiatry. 2003;31:155–76.CrossRefPubMedGoogle Scholar
  4. 4.
    Boecker R, Holz NE, Buchmann AF, Blomeyer D, Plichta MM, Wolf I, Baumeister S, Meyer-Lindenberg A, Banaschewski T, Brandeis D, Laucht M. Impact of early life adversity on reward processing in young adults: EEG-fMRI results from a prospective study over 25 years. PLoS ONE. 2014;9(8):e104185. doi: 10.1371/journal.pone.0104185.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Bolton D. Should mental disorders be regarded as brain disorders? 21st century mental health sciences and implications for research and training. World Psychiatry. 2013;12:24–5.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Bond GR, Drake RE. Predictors of competitive employment among patients with schizophrenia. Curr Opin Psychiatry. 2008;21:362–9.CrossRefPubMedGoogle Scholar
  7. 7.
    Bond GR, Drake RE, Rapp CA, et al. Individualization and quality improvement: two new scales to complement measurement of program fidelity. Adm Policy Ment Health. 2009;36:349–57.CrossRefPubMedGoogle Scholar
  8. 8.
    Borrell-Carrió F, Suchman AL, Epstein RM. The biopsychosocial model 25 years later: principles, practice, and scientific inquiry. Ann Fam Med. 2004;2:576–82.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Bradford DW, Cunningham NT, Slubicki MN, et al. An evidence synthesis of care models to improve general medical outcomes for individuals with serious mental illness: a systematic review. J Clin Psychiatry. 2013;74:e754–64. doi: 10.4088/JCP.12r07666.CrossRefPubMedGoogle Scholar
  10. 10.
    Brent BK, Holt DJ, Keshavan MS, et al. Mentalization-based treatment for psychosis: linking an attachment-based model to the psychotherapy for impaired mental state understanding in people with psychotic disorders. Isr J Psychiatry Relat Sci. 2014;51:17–24.PubMedGoogle Scholar
  11. 11.
    Calton T, Ferriter M, Huband N, et al. A systematic review of the Soteria paradigm for the treatment of people diagnosed with schizophrenia. Schizophr Bull. 2008;34:181–92.CrossRefPubMedGoogle Scholar
  12. 12.
    Cieza A, Stucki G. The international classification of functioning disability and health: its development process and content validity. Eur J Phys Rehabil Med. 2008;44:303–13.PubMedGoogle Scholar
  13. 13.
    Cieza A, Bickenbach J, Chatterji S. The ICF as a conceptual platform to specify and discuss health and health-related concepts. Gesundheitswesen. 2008;70:e47–56. doi: 10.1055/s-2008-1080933.CrossRefPubMedGoogle Scholar
  14. 14.
    Correll CU. From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics. Eur Psychiatry. 2010;25(Suppl 2):S12–21.CrossRefPubMedGoogle Scholar
  15. 15.
    Correll CU. Mechanism of action of antipsychotic medications. J Clin Psychiatry. 2014;75(9):e23. doi: 10.4088/JCP.13078tx4c.CrossRefGoogle Scholar
  16. 16.
    Cuthbert BN. The RDoC framework: facilitating transition from ICD/DSM to dimensional approaches that integrate neuroscience and psychopathology. World Psychiatry. 2014;13:28–35.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Cuthbert BN, NIMH RDoC Workgroup. The RDoC framework: continuing commentary. World Psychiatry. 2014;13:196–7.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Engel G. The need for a new medical model: a challenge for biomedicine. Science. 1977;196:129–36.CrossRefPubMedGoogle Scholar
  19. 19.
    European Network of National Networks studying Gene-Environment Interactions in Schizophrenia (EU-GEI), van Os J, Rutten BP et al. Identifying gene-environment interactions in schizophrenia: contemporary challenges for integrated, large-scale investigations. Schizophr Bull. 2014;40:729–736.Google Scholar
  20. 20.
    Ford JM, Morris SE, Hoffman RE et al. Studying hallucinations Within the NIMH RDoC Framework. Schizophr Bull. 2014; in press. doi: 10.1093/schbul/sbu011.
  21. 21.
    Gaebel W, Riesbeck M, von Wilmsdorff M, et al. Drug attitude as predictor for effectiveness in first-episode schizophrenia: results of an open randomized trial (EUFEST). Eur Neuropsychopharmacol. 2010;20:310–6.CrossRefPubMedGoogle Scholar
  22. 22.
    Gaebel W, Riesbeck M, Wobrock T. Schizophrenia guidelines across the world: a selective review and comparison. Int Rev Psychiatry. 2011;23:379–87.CrossRefPubMedGoogle Scholar
  23. 23.
    Gaebel W, Galderisi S, Gheorghe M, et al. Unmet needs in patients with first-episode schizophrenia: a longitudinal perspective. Psychol Med. 2012;42:1461–73.CrossRefGoogle Scholar
  24. 24.
    Gaebel W, Zäske H, Zielasek J et al. Stigmatization of psychiatrists and general practitioners: results of an international survey. Eur Arch Psychiatry Clin Neurosci. 2014a; Sep 5. [Epub ahead of print].Google Scholar
  25. 25.
    Gaebel W, Muijen M, Baumann AE. EPA guidance on building trust in mental health services. Eur Psychiatry. 2014;29:83–100.CrossRefPubMedGoogle Scholar
  26. 26.
    Garfield DA. Psychoanalytically informed psychotherapy of psychosis: the influences of american psychoanalysis. Panel report. J Am Psychoanal Assoc. 2011;59:603–20.CrossRefPubMedGoogle Scholar
  27. 27.
    Großimlinghaus I, Falkai P, Gaebel W, et al. Developmental process of DGPPN quality indicators]. [Article in German. Nervenarzt. 2013;84:350–65.CrossRefPubMedGoogle Scholar
  28. 28.
    Hornung WP, Feldmann R, Klingberg S, et al. Long-term effects of a psychoeducational psychotherapeutic intervention for schizophrenic outpatients and their key-persons–results of a five-year follow-up. Eur Arch Psychiatry Clin Neurosci. 1999;249:162–7.CrossRefPubMedGoogle Scholar
  29. 29.
    Howes OD, Egerton A, Allan V, et al. Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging. Curr Pharm Des. 2009;15:2550–9.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Kafka JS. Chestnut lodge and the psychoanalytic approach to psychosis. J Am Psychoanal Assoc. 2011;59:27–47.CrossRefPubMedGoogle Scholar
  31. 31.
    Klingberg S, Wölwer W, Engel C, et al. Negative symptoms of schizophrenia as primary target of cognitive behavioral therapy: results of the randomized clinical TONES study. Schizophr Bull. 2011;37(Suppl 2):S98–110.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Korver-Nieberg N, Berry K, Meijer CJ, et al. Adult attachment and psychotic phenomenology in clinical and non-clinical samples: a systematic review. Psychol Psychother. 2014;87:127–54.CrossRefPubMedGoogle Scholar
  33. 33.
    Landolt K, Rössler W, Burns T, et al. On the psychoanalytic treatment of a psychotic breakdown. Psychoanal Q. 2005;74:1069–99.Google Scholar
  34. 34.
    MacDonald-Wilson KM, Deegan PE, Hutchison SL, et al. Integrating personal medicine into service delivery: empowering people in recovery. Psychiatr Rehabil J. 2013;36:258–63.CrossRefPubMedGoogle Scholar
  35. 35.
    Magliano L, Read J, Sagliocchi A, et al. Social dangerousness and incurability in schizophrenia: results of an educational intervention for medical and psychology students. Psychiatry Res. 2014;219:457–63.CrossRefPubMedGoogle Scholar
  36. 36.
    Martindale BV. The rehabilitation of psychoanalysis and the family in psychosis: recovering from blaming. Psychiatr Danub. 2009;21(Suppl 1):51–60.PubMedGoogle Scholar
  37. 37.
    McGurk SR, Mueser KT, Feldman K, et al. Cognitive training for supported employment: 2–3 year outcomes of a randomized controlled trial. Am J Psychiatry. 2007;164:437–41.CrossRefPubMedGoogle Scholar
  38. 38.
    Moreno C, Nuevo R, Chatterji S, et al. Psychotic symptoms are associated with physical health problems independently of a mental disorder diagnosis: results from the WHO World Health Survey. World Psychiatry. 2013;12:251–7.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Nuevo R, Van Os J, Arango C. Evidence for the early clinical relevance of hallucinatory-delusional states in the general population. Acta Psychiatr Scand. 2013;127:482–93.CrossRefPubMedGoogle Scholar
  40. 40.
    Okpokoro U, Adams CE, Sampson S. Family intervention (brief) for schizophrenia. Cochrane Database Syst Rev 3. 2014;CD009802. doi: 10.1002/14651858.CD009802.pub2.
  41. 41.
    Ozomaro U, Wahlestedt C, Nemeroff CB. Personalized medicine in psychiatry: problems and promises. BMC Med. 2013;11:132.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Rector NA, Beck AT. Cognitive behavioral therapy for schizophrenia: an empirical review. J Nerv Ment Dis. 2012;200:832–9.CrossRefPubMedGoogle Scholar
  43. 43.
    Romme M, Morris M. The recovery process with hearing voices: accepting as well as exploring their emotional background through a supported process. Psychosis Psychol Soc Integr Appr. 2013;5:259–69.Google Scholar
  44. 44.
    Salvador-Carulla L, Mezzich JE. Person-centred medicine and mental health. Epidemiol Psychiatr Sci. 2012;21:131–7.CrossRefPubMedGoogle Scholar
  45. 45.
    Sandhu S, Bjerre NV, Dauvrin M. Experiences with treating immigrants: a qualitative study in mental health services across 16 European countries. Soc Psychiatry Psychiatr Epidemiol. 2013;48:105–16.CrossRefPubMedGoogle Scholar
  46. 46.
    Sarin F, Wallin L. Cognitive model and cognitive behavior therapy for schizophrenia: an overview. Nord J Psychiatry. 2014;68:145–53.CrossRefPubMedGoogle Scholar
  47. 47.
    Schennach R, Riedel M, Obermeier M, et al. Remission and recovery and their predictors in schizophrenia spectrum disorder: results from a 1-year follow-up naturalistic trial. Psychiatr Q. 2012;83:187–207.CrossRefPubMedGoogle Scholar
  48. 48.
    Schennach R, Meyer S, Seemüller F et al. Response trajectories in “real-world” naturalistically treated schizophrenia patients. Schizophr Res. 2012b;139:218–224.Google Scholar
  49. 49.
    Schennach R, Meyer S, Seemüller F, et al. Insight in schizophrenia-course and predictors during the acute treatment phase of patients suffering from a schizophrenia spectrum disorder. Eur Psychiatry. 2012;27:625–33.CrossRefPubMedGoogle Scholar
  50. 50.
    Schennach-Wolff R, Jäger M, Obermeier M, et al. Quality of life and subjective well-being in schizophrenia and schizophrenia spectrum disorders: valid predictors of symptomatic response and remission? World J Biol Psychiatry. 2010;11:729–38.CrossRefPubMedGoogle Scholar
  51. 51.
    Silver AL. Psychoanalytically informed treatment of psychosis: reflections on its U.S. history and current dilemmas. Psychoanal Rev. 2013;100:311–35.CrossRefPubMedGoogle Scholar
  52. 52.
    Spaeth-Rublee B, Pincus HA, Silvestri F, et al. Measuring quality of mental health care: an international comparison. Int J Environ Res Public Health. 2014;11:10384–9.CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Stanghellini G, Bolton D, Fulford WK. Person-centered psychopathology of schizophrenia: building on Karl Jaspers’ understanding of patient’s attitude toward his illness. Schizophr Bull. 2013;39:287–94.CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Straßmayr C, Matanov A, Priebe S, et al. Mental health care for irregular migrants in Europe: barriers and how they are overcome. BMC Publ Health. 2012;12:367. doi: 10.1186/1471-2458-12-367.CrossRefGoogle Scholar
  55. 55.
    Sullivan PF. Puzzling over schizophrenia: schizophrenia as a pathway disease. Nat Med. 2012;18:210–1.CrossRefPubMedPubMedCentralGoogle Scholar
  56. 56.
    Vasudev K, Martindale BV. Physical healthcare of people with severe mental illness: everybody’s business! Ment Health Fam Med. 2010;7:115–22.PubMedPubMedCentralGoogle Scholar
  57. 57.
    Weisman de Mamani A, Weintraub MJ, Gurak K et al. A randomized clinical trial to test the efficacy of a family-focused, culturally informed therapy for schizophrenia. J Fam Psychol. 2014 Oct 6. [Epub ahead of print].Google Scholar
  58. 58.
    Wittorf A, Jakobi UE, Bannert KK, et al. Does the cognitive dispute of psychotic symptoms do harm to the therapeutic alliance? J Nerv Ment Dis. 2010;198:478–85.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  1. 1.Proffessor, Department of Psychiatry and PsychotherapyHeinrich Heine UniversityDüsseldorfGermany

Personalised recommendations